Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer

Purpose: Chemoresistance in triple-negative breast cancer (TNBC) is associated with the activation of a survival mechanism orchestrated by the endoplasmic reticulum (EnR) stress response and by inducible nitric oxide synthase (iNOS). Our aim was to determine the effects of pharmacologic NOS inhibition on TNBC. Experimental Design: TNBC cell lines, SUM-159PT, MDA-MB-436, and MDA-MB-468, were treated with docetaxel and NOS inhibitor (L-NMMA) for 24, 48, and 72 hours. Apoptosis was assessed by flow cytometry using Annexin-V and propidium iodide. Western blot was used to assess ER stress and apoptosis, and rtPCR was used to evaluate s-XBP1. TNBC patient-derived xenografts (PDX) were treated either with vehicle, docetaxel, or combination therapy (NOS inhibition + docetaxel). Mouse weight and tumor volumes were recorded twice weekly. Docetaxel concentration was determined using mass spectrometry. To quantify proliferation and apoptosis, PDX tumor samples were stained using Ki67 and TUNEL assay. Results: In vitro, L-NMMA ameliorated the iNOS upregulation associated with docetaxel. Apoptosis increased when TNBC cells were treated with combination therapy. In TNBC PDXs, combination therapy significantly reduced tumor volume growth and increased survival proportions. In the BCM-5998 PDX model, intratumoral docetaxel concentration was higher in mice receiving combination therapy. Coupling docetaxel with NOS inhibition increased EnR-stress response via coactivation of ATF4 and CHOP, which triggered the pASK1/JNK proapoptotic pathway, promoting cleavage of caspases 3 and 9. Conclusions: iNOS is a critical target for docetaxel resistance in TNBC. Pharmacologic inhibition of NOS enhanced chemotherapy response in TNBC PDX models. Combination therapy may improve prognosis and prevent relapse in TNBC patients who have failed conventional chemotherapy. Clin Cancer Res; 24(5); 1152–62. ©2018 AACR.

[1]  J. Weiss,et al.  Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer , 2017, Proceedings of the National Academy of Sciences.

[2]  Jenny C. Chang,et al.  Abstract CT037: Clinical phase Ib trial of L-NMMA plus docetaxel in the treatment of refractory locally advanced or metastatic triple negative breast cancer patients , 2017 .

[3]  J. Pauli,et al.  Hypothalamic endoplasmic reticulum stress of overtrained mice after recovery , 2017 .

[4]  N. Prevarskaya,et al.  The calcium–cancer signalling nexus , 2017, Nature Reviews Cancer.

[5]  O. Elemento,et al.  Role of RPL39 in Metaplastic Breast Cancer , 2017, Journal of the National Cancer Institute.

[6]  Michael T. McManus,et al.  PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression , 2016, Nature Medicine.

[7]  M. Zoratti,et al.  Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. , 2016, Biochimica et biophysica acta.

[8]  G. Jerusalem,et al.  Triple-negative breast cancer: treatment challenges and solutions , 2016, Breast cancer.

[9]  G. Shapiro,et al.  ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[10]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[11]  K. Kashfi,et al.  The dual role of iNOS in cancer☆ , 2015, Redox biology.

[12]  Giorgio Mustacchi,et al.  The role of taxanes in triple-negative breast cancer: literature review , 2015, Drug design, development and therapy.

[13]  M. Rebucci,et al.  Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis. , 2015, The international journal of biochemistry & cell biology.

[14]  Hong Zhao,et al.  Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.

[15]  Å. Borg,et al.  Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. , 2014, Cancer research.

[16]  Stephen T. C. Wong,et al.  Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling , 2014, Proceedings of the National Academy of Sciences.

[17]  B. Yadav,et al.  Systemic treatment strategies for triple-negative breast cancer. , 2014, World journal of clinical oncology.

[18]  S. Ambs,et al.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.

[19]  M. Pawlus,et al.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells , 2014, Oncogene.

[20]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[21]  L. Vardy,et al.  RPL39L is an example of a recently evolved ribosomal protein paralog that shows highly specific tissue expression patterns and is upregulated in ESCs and HCC tumors , 2014, RNA biology.

[22]  A. Bonni,et al.  iNOS: a potential therapeutic target for malignant glioma. , 2013, Current molecular medicine.

[23]  H. Nakagawa,et al.  Selection of autophagy or apoptosis in cells exposed to ER-stress depends on ATF4 expression pattern with or without CHOP expression , 2013, Biology Open.

[24]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[25]  P. Fasching,et al.  Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer , 2013, Clinical Cancer Research.

[26]  A. Gadbail,et al.  Nitric oxide and cancer: a review , 2013, World Journal of Surgical Oncology.

[27]  F. Khuri,et al.  Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-IκB Kinase Cascade , 2013, Molecular and Cellular Biology.

[28]  Antonín Lojek,et al.  Arginine-Based Inhibitors of Nitric Oxide Synthase: Therapeutic Potential and Challenges , 2012, Mediators of inflammation.

[29]  A. Elias.  Triple-Negative Breast Cancer: A Short Review , 2010, American journal of clinical oncology.

[30]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[31]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[32]  J. Myers,et al.  Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy , 2010, Clinical Cancer Research.

[33]  N. Prevarskaya,et al.  Ion channels and the hallmarks of cancer. , 2010, Trends in molecular medicine.

[34]  R. Reeves,et al.  PIM1 Phosphorylates and Negatively Regulates ASK1-mediated Apoptosis , 2009, Oncogene.

[35]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[36]  P. Hersey,et al.  Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. , 2009, Neoplasia.

[37]  H. Ichijo,et al.  The roles of ASK family proteins in stress responses and diseases , 2009, Cell Communication and Signaling.

[38]  John Calvin Reed,et al.  Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities , 2008, Nature Reviews Drug Discovery.

[39]  L. Lan,et al.  Effect of amlodipine on apoptosis of human breast carcinoma MDA-MB-231 cells , 2008 .

[40]  Nizar M. Mhaidat,et al.  Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma , 2008, Apoptosis.

[41]  Vijay S Pande,et al.  Side-chain recognition and gating in the ribosome exit tunnel , 2008, Proceedings of the National Academy of Sciences.

[42]  D. Calvisi,et al.  Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. , 2008, Carcinogenesis.

[43]  M. Lilly,et al.  The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[44]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[45]  S. Huh,et al.  PBISe, a novel selenium-containing drug for the treatment of malignant melanoma , 2008, Molecular Cancer Therapeutics.

[46]  Daniel L. Gustafson,et al.  A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man , 2007, Clinical Cancer Research.

[47]  Afshin Samali,et al.  Mediators of endoplasmic reticulum stress‐induced apoptosis , 2006, EMBO reports.

[48]  Z. Shang,et al.  In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. , 2006, International journal of oral and maxillofacial surgery.

[49]  R. Sokol,et al.  The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.

[50]  W. Min,et al.  Hsp90–Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis , 2005, Oncogene.

[51]  H. E. Marshall,et al.  Protein S-nitrosylation: purview and parameters , 2005, Nature Reviews Molecular Cell Biology.

[52]  C. Rao.  Nitric oxide signaling in colon cancer chemoprevention. , 2004, Mutation research.

[53]  S. Oyadomari,et al.  Roles of CHOP/GADD153 in endoplasmic reticulum stress , 2004, Cell Death and Differentiation.

[54]  H. Fu,et al.  Activation of Apoptosis Signal-regulating Kinase 1 by Reactive Oxygen Species through Dephosphorylation at Serine 967 and 14-3-3 Dissociation* , 2004, Journal of Biological Chemistry.

[55]  Mi-Sung Kim,et al.  Inhibition of Apoptosis Signal-regulating Kinase 1 by Nitric Oxide through a Thiol Redox Mechanism* , 2004, Journal of Biological Chemistry.

[56]  V. Steele,et al.  Is inducible nitric oxide synthase a target for chemoprevention? , 2003, Molecular cancer therapeutics.

[57]  D. Gustafson,et al.  Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay , 2003, Cancer Chemotherapy and Pharmacology.

[58]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Kiyoshi Inoue,et al.  ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. , 2002, Genes & development.

[60]  V. Kosma,et al.  Inducible Nitric Oxide Synthase Expression in Pharyngeal Squamous Cell Carcinoma: Relation to p53 Expression, Clinicopathological Data, and Survival , 2002, The Laryngoscope.

[61]  H. Ichijo,et al.  Activation of apoptosis signal‐regulating kinase 1 by the stress‐induced activating phosphorylation of pre‐formed oligomer , 2002, Journal of cellular physiology.

[62]  K. Mori,et al.  XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor , 2001, Cell.

[63]  K. Rg,et al.  Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. , 2000 .

[64]  T. Tsuruo,et al.  ASK1 mediates apoptotic cell death induced by genotoxic stress , 1999, Oncogene.

[65]  C. Szabó,et al.  BENEFICIAL VERSUS DETRIMENTAL EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITORS IN CIRCULATORY SHOCK LESSONS LEARNED FROM EXPERIMENTAL AND CLINICAL STUDIES , 1997, Shock.

[66]  Minoru Takagi,et al.  Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways , 1997, Science.

[67]  F. Behm,et al.  cDNA cloning, tissue distribution, and chromosomal localization of myelodysplasia/myeloid leukemia factor 2 (MLF2). , 1996, Genomics.

[68]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human breast cancer. , 1995, British Journal of Cancer.

[69]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[70]  J. Taylor,et al.  Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. , 1992, Cancer research.

[71]  O. Griffith,et al.  Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. , 2000, The cancer journal from Scientific American.

[72]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[73]  Gaso-Transmitters Nitric oxide: what’s new to NO? , 2022 .